Melanoma Test Results Have Predicted Recurrence Risk
New clinical data suggest that specific test results can help guide melanoma surveillance and biopsy decisions.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Do you trust diagnostic test results to guide your personal medical treatment decisions?
Researchers have demonstrated that the DecisionDx-Melanoma test can accurately predict the risk of sentinel lymph node positivity and disease recurrence in patients. These findings may assist clinicians in making more informed decisions regarding whether to proceed with a sentinel lymph node biopsy.
Why it matters
This development provides a clearer path for managing early-stage melanoma by identifying which patients may safely avoid invasive biopsy procedures while maintaining high recurrence-free survival rates. It helps address clinical uncertainty, particularly when staging is difficult to confirm.
A clinical analysis demonstrated that patients with low-risk DecisionDx-Melanoma scores had a sentinel lymph node positivity rate of less than 5%. Eligible patients who bypassed sentinel lymph node biopsy achieved a five-year recurrence-free survival rate of 99.6%.
The players
EADV Congress
An international professional organization focused on advancements in dermatology and venereology research.
DecisionDx-Melanoma
A gene expression profile test designed to assess recurrence risk and sentinel lymph node positivity in patients with cutaneous melanoma.
The details
The DecisionDx-Melanoma test evaluates gene expression profiles to determine the biological aggressiveness of a tumor. The assay identifies early-stage, transected melanomas that carry a recurrence risk similar to stage IIB disease, allowing providers to tailor surveillance intensity. By clarifying the likelihood of lymph node involvement, the test supports evidence-based choices about the necessity of surgical staging.
Timeline
2026: New data regarding test accuracy were presented at the EADV congress.
Health Landscape
The standard of care for melanoma relies heavily on sentinel lymph node biopsies for staging and prognosis. This new evidence adds to the evolving landscape of molecular testing, which seeks to refine risk stratification and reduce unnecessary surgical procedures.
If you are undergoing treatment for melanoma, this research highlights the role that molecular testing can play in your personalized staging and care plan. Discuss these diagnostic options with your dermatologist or oncologist to determine if test results are relevant to your surveillance strategy.
The takeaway
The study validates a method to better predict melanoma recurrence risk, potentially sparing some patients from invasive surgical procedures. Tracking personal diagnostic markers and discussing your specific risk profile with a specialist remain essential for managing long-term health.
Further reading
For more information on current screening and diagnostic standards, visit our section on Cancer.
Live Poll
Do you trust diagnostic test results to guide your personal medical treatment decisions?
